Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ETCompany ParticipantsAlbert Bourla - Chairman of ...

Pfizer is gearing up for a federal preemption defense, its first fight designed to wipe out more than 400 lawsuits over ...

Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. | Axsome ...

SCHD remains a particularly attractive investment option for long-term investors. Check out how to build a $75,000 dividend ...

Shares of Pfizer Inc. PFE rallied 2.66% to $23.97 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.09% to 6,005.88 and the Dow ...

In the most recent trading session, Dow Inc. (DOW) closed at $29.39, indicating a +2.94% shift from the previous trading day.

Market report includes a comprehensive understanding of current treatment practices, emerging HER2+ gastric cancer therapies, market share of individual therapies, and current and forecasted HER2+ ...

Selective estrogen receptor modulators are advancing notably in treating hormone‐driven conditions, offering opportunities across oncology and women' ...